Radiation victim management and the haematologist in the future: time to revisit therapeutic guidelines?
OBJECTIVE
The use of nuclear/radiation devices against the civilian population is now a realistic scenario. Haematopoietic syndrome is the primary therapeutic challenge in the case of whole body acute exposure over 2 Grays (Gy) whereas burns and combined injuries would be frequently observed in myelo-suppressed patients. Optimisation of scoring and treatments are important goals to achieve.


CONCLUSIONS
The European Response Category (RC) concept represents an attempt to integratively assess haematological/extrahematological radiation-induced lesions. Based on the frequently observed heterogeneity of bone marrow damage in accidental/intentional irradiations, the stimulation of residual stem cells using granulocyte Colony-stimulating factor remains the therapeutic standard after exposure to less than the lethal dose 50 % (Haematopoietic[H] score 3-H3). Allogeneic stem cell transplantation is indicated in case of medullary eradication (Haematopoietic score 4-H4) whereas extramedullary toxicity may determine the outcome. Especially in case of numerous casualties exhibiting acute radiation syndrome, the administration of survival factor combinations remains questionable, at least as a palliative treatment. In addition pleiotropic cytokines injection such as erythropoietin and keratinocyte growth factor and grafting multipotent mesenchymal stem cells - from underexposed bone marrow areas or fat tissues - could be proposed to prevent multiple organ failure syndrome development. Multi-disciplinary teams should be prepared to manage such patients.
Drouet
Michel
M
IRBA-antenne La Tronche-CRSSA, La Tronche, France. micheldrouet@crssa.net
Hérodin
Francis
F
D000818:Animals; D017209:Apoptosis; D016207:Cytokines / Q000627:therapeutic use; D006405:Hematology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009102:Multiple Organ Failure / Q000209:etiology; D017410:Practice Guidelines as Topic; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000628:therapy*; D018788:Radioactive Hazard Release; D012867:Skin / Q000528:radiation effects; D034061:Thrombopoiesis / Q000187:drug effects
D016207:Cytokines